Professor Susan Duty & Team

Institute of Psychiatry, Psychology & Neuroscience, King's College London

We are delighted to work with Professor Andy Whiting and colleagues from Nevrargenics. Their novel class of retinoid acid receptor modulators have real potential to address the neurodegeneration in Parkinson's disease. There are currently no drugs that can achieve this, so the prospect of finding new treatments through such a friendly and fast-paced collaboration, combining their chemical excellence with our expertise in modelling Parkinson's is very exciting.

Dr Mark Baker

Consultant Clinical Neurophysiologist/Neurologist, Institute of Neuroscience, Newcastle University

In ALS, there is a desperate need for compounds that act at novel therapeutic targets to halt or slow disease progression. Nevrargenics have a range of such compounds and I am excited to be collaborating with them, and to have the opportunity to test their compounds in pre-clinical models of ALS.

Professor Peter Coveney

Professor of Physical Chemistry, University College London

One of the key areas we specialise in the Computational Chemistry Group in Chemistry and UCL, is the development of models from nano- to macro-scales, especially the modelling and understanding complex biological systems, from receptor-ligand binding right up to whole human systems. At the smaller end of that scale, we have been collaborating with Professor Whiting at Durham University, and now the Nevrargenics team, to develop more accurate retinoid-ligand binding models and the accurate calculation of the energies of binding. This type of approach could not only be game changing for the genuine ab initio design of the next generation of retinoid drugs, support our understanding of their mode of action, and help drive the invention of truly disease modifying drugs for what are currently, a wide range of neurodegenerative diseases.

Dr Paul Chazot

Fellow of the Wolfson Research Institute for Health and Wellbeing

Parkinsons is the fastest growing neurological disease which still lacks a disease-modifying therapy. We have a billion neurological disease sufferers worldwide with little or no effective long-lasting treatment options. Retinoic Acid Receptor-modulating drugs are a realistic new option for effective treatments of Neurodegenerative diseases.